| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | Myopharm is an IND stage biotechnology company focused on developing first in class, novel therapeutics for the treatment and prevention of Type 2 diabetes. Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza‚Ñ¢ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza‚Ñ¢ to market by 2027. https://www.myopharm.com |
| Category: | Hardware & devices, Health & biotech |
| URL: | https://www.myopharm.com |
| Operational Status: | |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | |
| Address: | 60 Martin Pl, Levels 1,2&3, Sydney, New South Wales 2000, AU |
| State: | New South Wales |
| Overseas Operations: | |
| X: | |
| Facebook: | |
| Linkedin: | https://linkedin.com/company/myopharmltd |
| Founders: | |
| Awards won: | |
